Clinical study explains about drug dosage during high BP

The findings focus on patients whose initial systolic blood pressure was above 130 mm Hg.

Blood Pressure BP
Picture: Pixabay

Last Updated on October 12, 2021 by The Health Master

Washington: In a look back at data from nearly 179,000 veterans over age 65 who received treatment over two years at VA hospitals nationwide, researchers find that patients have a better chance of sticking to their medication regimen if their doctor maximises the dosage of one of the drugs they’re already taking.

The findings of the study published in the journal ‘Annals of Internal Medicine’, may help doctors and people with high blood pressure (BP) to decide whether to increase the dose of existing drugs or add a new one, to bring down their pressure and lower the risk of future health problems.

They also found that both strategies decrease blood pressure, but adding a new medication has a very slim advantage over increasing the dose of an existing medication, despite some of the patients being unable to stay on the new medication.

In the end, the researchers say, the new findings could add to discussions between physicians and patients whose blood pressure remains elevated despite starting a medication treatment.

The findings focus on patients whose initial systolic blood pressure was above 130 mm Hg.

By looking back at VA and Medicare data, the researchers were able to see patterns in treatment and blood pressure readings over time, in a kind of natural experiment.

All the patients were taking at least one blood pressure medication at less than the maximum dose and had a treatment intensification at the start of the study period, indicating that their physicians thought they needed more intense treatment.

Because intensification of blood pressure treatment can come with risks — whether a drug interaction if a new drug is added, or an electrolyte imbalance with high doses, or fainting and falling if a person’s pressure gets too low — such decisions must be carefully made.

This is the first time a study has directly compared the effects of the two approaches, said first author Carole E. Aubert, MD, MSc, a general internist from Bern University in Switzerland who performed much of the research while a scholar at the U-M Institute for Healthcare Policy and Innovation.

“There’s increasing guidance on approaches to starting treatment in older adults, but less on to the next steps to intensify treatment, especially in an older and medically complex population that isn’t usually included in clinical trials of blood pressure medication,” she said.

“How can we increase medications safely in a population already taking many medications for hypertension and other conditions,” she added.

“Treatment guidelines do suggest starting treatment with multiple medications, and clinicians are comfortable with an approach of ‘starting low and going slow’ in older patients,” said senior author Lillian Min, MD, MSHS.

“But these results show that in older patients, we have further opportunity to tailor choices in intensifying drug therapy for hypertension, depending on the individual patient’s characteristics,” added Min.

“Is the patient more likely to stick to a simpler regimen? Then increase an existing medication. Or is the blood pressure very high and the clinician is more concerned about reducing it? Then consider starting a new medication now,” continued Min.

Min is a geriatrician at the Division of Geriatrics and Palliative Care at Michigan Medicine, U-M’s academic medical centre, and the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center.

For older adults who already take a range of medications, the added complexity of having to take one more kind of pill may be too much. The risks of polypharmacy, the term for taking multiple medications, are already well-known from other research, Min said.

In fact, Medicare covers an annual medication review with a pharmacist for many older adults who take many drugs.

Australian regulator approves Lincoln Pharma’ Gujarat plant for GMP

USFDA gives tentative nod to Zydus Cadila for Adapalene and Benzoyl…

Gujarat FDCA organized conference on Pharma Sector in Dubai

Govt applies quantitative restriction on export of certain types of syringes

Aurobindo Pharma, MSN Labs seek DCGI nod for Phase-III trials of…

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon